Filing identity and reporting period
The supplied filing is Tokai Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2016—not a filing identified as Eledon Pharmaceuticals, Inc. Investors should verify the issuer before relying on this summary.
Tokai was a development-stage biopharmaceutical company focused on prostate cancer and other hormonally driven diseases. It had no approved products and had generated no revenue.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data. The filing presents no product revenue, so revenue margins are not meaningful.
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $6.162 | $8.491 | $23.988 | $24.905 |
| General and administrative | $3.146 | $3.416 | $10.375 | $9.284 |
| Total operating expenses | $9.308 | $11.907 | $34.363 | $34.189 |
| Net loss | $(9.270) | $(11.853) | $(34.222) | $(34.070) |
| Net loss per share, basic and diluted | $(0.41) | $(0.53) | $(1.51) | $(1.52) |
- Cash and cash equivalents were $18.630 million and marketable securities were $16.088 million at September 30, 2016, totaling $34.718 million in cash and investments, versus $63.957 million at December 31, 2015.
- Current assets were $36.334 million; current liabilities were $6.344 million. Total liabilities were $6.464 million. The balance sheet lists no borrowings; the filing does not provide a separate debt balance.
- Operating cash use was $29.210 million for the first nine months, compared with $32.359 million in 2015. Investing activities provided $23.780 million, primarily reflecting maturities of marketable securities. Cash and cash equivalents declined $5.393 million during the period.
- Accumulated deficit was $165.660 million. The company recorded no income tax provision for the nine-month periods presented.
Material changes and significant events
- Q3 net loss narrowed by $2.583 million year over year as operating expenses fell $2.599 million, mainly because of lower galeterone clinical-trial costs after the ARMOR3-SV trial was discontinued. Nine-month net loss increased $0.152 million, as slightly higher G&A more than offset lower R&D.
- Tokai announced in July 2016 that it would discontinue its pivotal Phase 3 ARMOR3-SV trial after the independent data monitoring committee concluded the trial was unlikely to meet its primary endpoint of improved radiographic progression-free survival versus enzalutamide. The committee did not cite safety concerns.
- In August, the company stopped enrollment in the Phase 2 ARMOR2 expansion trial and abandoned a planned study in patients progressing rapidly on enzalutamide or abiraterone. It continued to follow 11 ARMOR2 patients as of October 31, 2016.
- The company reduced its workforce by approximately 60% to 10 full-time-equivalent employees. It recorded $1.2 million of related costs in Q3, with $0.9 million accrued at quarter-end and expected remaining payments in Q4 2016 and Q1 2017.
- Tokai recorded a $1.099 million R&D charge for the final payment to Qiagen following termination of the companion-diagnostic project work plan.
Outlook, risks, and contingencies
- Management estimated that September 30 cash and investments would fund operations for at least 12 months, conditional on no new clinical efforts for galeterone or another product candidate. Resuming development of galeterone, advancing the ARDA discovery program, or both would require substantial additional funding; future needs were uncertain.
- The board began a strategic-alternatives review, potentially including a sale, reverse merger, business combination, or sale or licensing of assets. The company gave no assurance that the review would produce a transaction or a specific outcome.
- Tokai was analyzing unblinded ARMOR3-SV data. Based on preliminary review, management said there was a substantial likelihood it would not pursue galeterone for AR-V7-positive metastatic castration-resistant prostate cancer. The ARDA program’s most advanced compounds were in preclinical development.
- Three putative shareholder class actions alleged misleading statements or omissions concerning galeterone trials and/or the IPO. Tokai said it intended to defend the cases but could not estimate potential losses; an unfavorable outcome could materially affect results and cash flows.
- Other key risks included continued losses and reliance on additional capital, clinical and regulatory uncertainty, dependence on third-party manufacturers and trial providers, intellectual-property risks, competition, and possible disruption or failure to realize savings from the workforce reduction.
- A related-party consulting agreement with Apple Tree Life Sciences, whose affiliates beneficially owned approximately 35% of Tokai and whose principal was a director, provided for services without a fee other than expense reimbursement.
Important facts for investors to verify
- Confirm the issuer: the filing names Tokai Pharmaceuticals, Inc., not Eledon Pharmaceuticals, Inc.
- Review subsequent disclosure of ARMOR3-SV’s complete unblinded results and management’s decisions on galeterone and ARDA.
- Check the outcome of the strategic review, actual cash runway, and any financing or transaction announcements.
- Track the Qiagen termination payment, restructuring costs and savings, and the status and potential exposure of the shareholder lawsuits.